Statement re Issuance of US Patent

PROTEOME SCIENCES plc Issuance of US Patent for Isobaric Tandem Mass Tags® (TMT®) 13 November 2007. Proteome Sciences plc ("Proteome Sciences") announces the issuance of US Patent Number 7,294,456 entitled Mass Labels relating to isobaric tandem mass tags (TMT®). Patents covering the TMT technologies are now issued in Australia, New Zealand, Canada, Europe and the USA. The US Patent contains broad claims to sets of isobaric mass tags. Commenting on the Issuance of US Patent Number 7,254,456 Christopher Pearce, CEO of Proteome Sciences said: "Following the issuance of the TMT1 patent in Europe, we are delighted today to have obtained the issuance of the TMT1 patent in the US. The issued TMT patents provide Proteome Sciences broad claims across the field of isobaric tandem mass tagging, with the ability to now exploit TMT® in these substantial markets both as a product in its own right, and for third party licences for the manufacture or use of any type of isobaric tandem mass tags. The patent issuance should allow us to complete commercialisation and outlicensing of TMT® and to generate strong revenue through licence income, product sales and royalties in the rapidly growing market and applications for isobaric tandem mass tagging in biomarker discovery, validation and assay development across a broad range of applications including clinical research and in vitro diagnostics." Ends Notes to editors: Proteome Sciences plc applies high sensitivity proteomics to identify and characterise differential protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has discovered blood biomarkers principally for stroke, vCJD, BSE, brain damage, solid organ transplant rejection and Alzheimer's disease. The main focus of its research currently addresses neurological, neurodegenerative, oncology and cardiovascular conditions. In addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoSHOP® (Proteome Sciences High Output Proteomics), a toolbox that offers high sensitivity and high throughput gel and gel-free proprietary technologies for the identification and validation of potential biomarkers and drug targets, including specialisation in membrane proteins and protein phosphorylation. The Company has developed a range of specialist reagents to improve the performance and quantitation of protein separation and characterisation with mass spectrometry, bioinformatics, statistics and pattern recognition. These include Sensitizer®, PST®, qPST™ and TMT®. Proteome Sciences has patent allowances in the major global jurisdictions for isobaric tandem mass tags (TMT ®) for the manufacture and use of any type of isobaric mass tags. Commercialisation is actively pursued across the portfolio of the Company's programmes and technologies with licensing deals signed in biomarkers for Stroke and TSEs and for ProteoSHOP®. Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has laboratories at Kings College Hospital, London and Frankfurt Innovations Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its corporate and business development staff, and has collaborative research agreements with leading academic institutes. The Company is listed on the Alternative Investment Market. For further information please visit www.proteomics.com . Proteome Sciences plc Dr. Ian Pike, Business Development Director Email: ian.pike@proteomics.com Christopher Pearce, Chief Executive Officer Email: christopher.pearce@proteomics.com Tel: +44 (0)1932 865065 Public Relations IKON Associates Coast Communications Adrian Shaw Tel: +44 (0)1483 535102 Mobile: +44 (0)797 9900733 Email: adrian@ikonassociates.com Matt Baldwin Tel: +44 (0)1233 503200 Mobile: +44 (0)7930 439739 Email: matt@coastcommunications.com Nominated Adviser Landsbanki Securities (UK) Ltd Gareth Price / Thilo Hoffman Tel: +44 (0)20 7426 9000